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Substrate discriminationETT (originally designated as OCTN1; human gene symbol SLC22A4) and CTT (OCTN2; SLC22A5) are highly
speciﬁc transporters of ergothioneine and carnitine, respectively. Despite a high degree of sequence
homology, both carriers discriminate precisely between substrates: ETT does not transport carnitine, and CTT
does not transport ergothioneine. Our aim was to turn ETT into a transporter for carnitine and CTT into a
transporter for ergothioneine by a limited number of point mutations. From a multiple alignment of several
mammalian amino acid sequences, those positions were selected for conversion that were momentously
different between ETT and CTT from human but conserved among all orthologues. Mutants were expressed
in 293 cells and assayed for transport of ergothioneine and carnitine. Several ETT mutants clearly catalyzed
transport of carnitine, up to 35% relative to wild-type CTT. Amazingly, complementary substitutions in CTT
did not provoke transport activity for ergothioneine. In similar contrast, carnitine transport by CTT mutants
was abolished by very few substitutions, whereas ergothioneine transport by ETT mutants was maintained
even with the construct most active in carnitine transport. To explain these results, we propose that ETT and
CTT use dissimilar pathways for conformational change, in addition to incongruent substrate binding sites. In
other words, carnitine is excluded from ETT by binding, and ergothioneine is excluded from CTT by turnover
movement. Our data indicate amino acids critical for substrate discrimination not only in transmembrane
segments 5, 7, 8, and 10, but also in segments 9 and 12 which were hitherto considered as unimportant.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Based on the analysis of transport efﬁciency, we have recently
established that the transport proteins originally designated as novel
organic cation transporters OCTN1 (human gene symbol SLC22A4)
and OCTN2 (SLC22A5) are in fact highly speciﬁc transporters of
ergothioneine (ET) and carnitine (CT), respectively [1–3]. We thus
have introduced previously the functional names ETT and CTT. An
alignment and comparison of amino acid sequences indicates that ETT
and CTT, e.g., from human are very closely related, with 77% identity
and 82% similarity. In other words, out of 551 or 557 amino acids,
respectively, only 133 positions are unequal. Despite the high degree
of sequence homology, both carriers discriminate precisely between
ET and CT: ETT does not transport CT, and CTT does not transport ET
[1,3].
ET and CT contain some common structural elements (Fig. 1), so
the substrate binding surfaces likely are identical in some parts. Since
Na+ drives uptake with both carrier types, this may be true, fororter; ET, ergothioneine; ETT,
MPP+, 1-methyl-4-phenylpyr-
segment
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ll rights reserved.example, for the sodium binding site. However, in order to achieve
speciﬁcity, other parts must be different. Obviously, substrate
discrimination is entirely determined by the 133 positions with
unequal amino acids. We expect that many of these differences are
irrelevant for substrate discrimination (evolutionary noise [4]); thus,
only a small subset of the 133 positionswith unequal amino acidsmay
be responsible for substrate discrimination.
The aim of the present study was to turn ETT into a transporter for
CT and CTT into a transporter for ET by a limited number of point
mutations. Such a gain-of-function conversion presents an outstand-
ing opportunity to identify the amino acids that determine substrate
discrimination in integral membrane transport proteins.
2. Materials and methods
2.1. Plasmid constructs
The cDNAs of ETT from human (ETTh) and CTT from human (CTTh)
were available from previous studies [1]. For easy generation and
combination of mutations, each transporter was divided into 4 parts.
Fragments with Esp3I, BspQI, or NcoI restriction sites at the ends were
generated by PCR and cloned into pUC19. Mutations were generated
with the QuikChange® II Kit (Stratagene, Agilent Technologies,
Waldbronn, Germany); all inserts were fully sequenced to verify the
Fig. 1. Structures of L-carnitine (CT) and L-ergothioneine (ET).
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fragments plus an eGFP fragment were ligated into expression vector
pEBTetD [5] that had been modiﬁed in the polylinker between the
HindIII and NotI sites. For wild-type and mutant ETTh plasmids, the
5′-interface between pEBTetD and cDNA is GTTTAAACTTAAGCTT
gccacc ATGCGGGACTACGAC (plasmid polylinker in bold, Kozak motif
lowercase, cDNA underlined); the interface between ETTh and eGFP
(in italics) is AGGTTCTAATAACTGCATTC tcc ATGGTGAGCAAGGGCGAG;
and the interface of eGFP and polylinker is GAGCTGTACAAGTAA a
GCGGCCGCGGG. For wild-type and mutant CTTh plasmids, the 5′-
interface between pEBTetD and cDNA is GTTTAAACTTAAGCTT gccacc
ATGCGGGACTACGAC; the interface between CTTh and eGFP is
TCCTTAAAAGCACAGCCTTC tcc ATGGTGAGCAAGGGCGAG; and the
interface of eGFP and polylinker is as above. Finally, the entire
transporter open reading frame of all assembled mutants was
sequenced for veriﬁcation.
2.2. Cell culture
293 cells (ATCC CRL-1573; also known as HEK-293 cells), a
transformed cell line derived from human embryonic kidney, were
grown at 37 °C in a humidiﬁed atmosphere (5% CO2) in plastic culture
ﬂasks (Falcon 3112, Becton Dickinson, Heidelberg, Germany). The
growth medium was Dulbecco's modiﬁed Eagle medium (Life
Technologies 31885-023, Invitrogen, Karlsruhe, Germany) supple-
mentedwith 10% fetal calf serum (PAA Laboratories, Cölbe, Germany).
Medium was changed every 2–3 days and the culture was split every
5 days.
Stably transfected cell lines were generated as reported previously
[5]; cell culture medium always contained 3 μg/ml puromycin (PAA
Laboratories) to ascertain plasmid maintenance. To turn on protein
expression, cells were cultivated for at least 20 h in regular growth
medium supplemented with 1 μg/ml doxycycline (195044, MP
Biomedicals, Eschwege, Germany).
2.3. Transport assays
For measurement of solute uptake, cells were grown in surface
culture on 60-mmpolystyrol dishes (Nunclon 150288, Nunc, Roskilde,
Denmark) precoated with 0.1 g/l poly-L-ornithine in 0.15 M boric
acid–NaOH, pH 8.4. Cells were used for uptake experiments at a
conﬂuence of at least 70%. Uptake was measured at 37 °C. Uptake
buffer contains 125 mmol/l NaCl, 25 mmol/l HEPES–NaOH pH 7.4,
5.6 mmol/l (+)glucose, 4.8 mmol/l KCl, 1.2 mmol/l KH2PO4,
1.2 mmol/l CaCl2, and 1.2 mmol/l MgSO4. After preincubation for
at least 20 min in 4 ml of uptake buffer, the buffer was replaced with
2 ml of substrate in uptake buffer. The total substrate concentration
if not indicated otherwise was 0.1 μmol/l for radiotracer assays (3H-
carnitine) and 10 μmol/l for unlabeled compounds (ET). Incubation
was stopped after 1 min by rinsing the cells four times each with
4 ml ice-cold uptake buffer. Radioactivity was determined, after cell
lysis with 0.1% vol./vol. Triton X-100 in 5 mmol/l TRIS–HCl pH 7.4,
by liquid scintillation counting. For LC-electrospray ionization-MS/
MS analysis, the cells were lysed with 4 mmol/l HClO4 and stored at−20 °C. After centrifugation (1 min, 16,000×g, 20 °C) of thawed
lysates, 100 μl of the supernatant was mixed with 10 μl unlabeled
MPP+ iodide (0.5 ng/μl) which served as internal standard. Of this
mixture, 20 μl samples were analyzed by LC-MS/MS (ﬂow rate
250 μl/min) on a triple quadrupole mass spectrometer (4000 Q
TRAP, Applied Biosystems, Darmstadt, Germany). Atmospheric
pressure ionization with positive electrospray was used. Isocratic
chromatography (70% methanol and 30% 0.1% formic acid) was
employed with a Waters Atlantis HILIC silica column (length 50 mm,
diameter 3 mm, particle size 5 μm). For quantiﬁcation (scan time
150 ms), the optimal collision energy for argon-induced fragmen-
tation in the second quadrupole was determined for each analyte.
From the product ion spectra, the following fragmentations were
selected for selected reaction monitoring (m/z parent, m/z fragment,
collision energy): ergothioneine: 230, 127, 27 V; MPP+: 170, 128,
43 V. For each analyte, the area of the intensity vs. time peak was
integrated and divided by the area of the MPP+ peak to yield the
analyte response ratio. Linear calibration curves were constructed
from at least six standards which were prepared using control cell
lysates as solvent. Sample analyte content was calculated from the
analyte response ratio and the slope of the calibration curve,
obtained by linear regression.
Protein was measured by the BCA assay (Pierce) with bovine
serum albumin as standard. The protein content of MS samples was
estimated from 3 matched cell dishes.
2.4. Calculations and statistics
The clearance equals initial rate of speciﬁc uptake (=uptake
mediated by expressed carrier) divided by substrate concentration; it
is directly proportional to kcat/Km (kcat: turnover number) and thus a
valid measure of efﬁciency of transport (provided that the substrate
concentration is much smaller than the respective Km) [6,7]. Speciﬁc
uptake equals total uptake minus uptake into control cells (=non-
speciﬁc uptake).
Analysis of saturation curves has been reported previously [8]. Km
values are given as geometric mean with 95% conﬁdence interval. In
the ﬁgures, symbols and bars represent arithmetic mean±SEM
(n=3) if not indicated otherwise in the legend.
2.5. Chemicals
Unlabeled compounds were as follows: L-carnitine (C-0283,
Sigma-Aldrich, Munich, Germany), L-ergothioneine (F-3455, Bachem,
Bubendorf, Switzerland), 1-methyl-4-phenylpyridinium iodide (D-
048, Sigma-Aldrich). All other chemicals were at least of analytical
grade. Radiotracer: L-carnitine hydrochloride (H-3, 3.1 kBq/pmol,
ART-293, ARC, St. Louis, MO, USA).
3. Results
3.1. Strategy of selection of substitutions
All substitutions were simply made according to the alignment of
the amino acid sequences of ETT from human (ETTh) and CTT from
human (CTTh) (Supplementary Fig. 1). Since it is not feasible to create
and analyze all possible combinations of all 133 transitions, the
challengewas to select what might be relevant substitutions.We used
evolutionary conservation as our prime indicator of relevance.
Although ETT and CTT apparently are present in vertebrates in
general (e.g., birds, reptiles, and ﬁshes), we included, for a high level
of basic similarity, only mammalian orthologues in evolutionary
analysis. Thus, a multiple alignment of the amino acid sequences of
ETT and CTT from human, pig, cattle, dog, mouse, and rat was
generated (Supplementary Fig. 1). We then selected those positions
that were strikingly different between ETTh and CTTh, but conserved
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ﬁrst 230 positions qualiﬁed, no substitutions at all were made in this
high similarity region.
3.2. ETTh mutants—carnitine transport
The ﬁrst set of ETTh mutants contained substitutions in trans-
membrane segments (TMS) 5, 7, 10, and 11. Most of thesewe consider
as potentially momentous: removal or addition of a hydroxyl group
(T⇔ I, L⇔T, F⇔Y, A⇔S), aromatic side chain (V⇔F), or glycine
(A⇔G). All mutants are speciﬁed in Table 1. In order to keep theTable 1
Designation and deﬁnition of mutants.
Black boxes indicate mutants (“e”) based on wild-type ETTh, and gray boxes mark mutant
indicates an amino acid in a loop.number of constructs manageable, we have grouped together
substitutions from the same TMS.
All constructs contained eGFP at the C-terminus in order to verify
uniform membrane trafﬁcking. Our experience (unpublished data)
suggests that such an attachment has no inﬂuence on transport
activity. All mutants described in this work showed similar expression
levels (FACS analysis, data not shown) and membrane localization
(ﬂuorescence microscopy; Supplementary Fig. 2) as the respective
wild-type carriers. Mutants were generated by site-directed muta-
genesis, inserted into our pEBTetD expression vector and stably
transfected into 293 cells. pEBTetD is an episomal Epstein–Barrs (“c”) based on wild-type CTTh. A capital “L” in row TMS (transmembrane segment)
Fig. 2. Signal-to-noise in transport assays with wild-type ETTh or CTTh. 293 cells were
stably transfected with either pEBTetD/ETTh-eGFP or pEBTetD/CTTh-eGFP. Expression
of transporter cDNA was turned on by addition of doxycycline. Cells grown in dishes
were incubated for 1 min with substrate (3.3 μmol/l unlabeled ET or 1.0 μmol/l 3H-CT)
in uptake buffer and then processed as described in Materials and methods. On-state
accumulation (=100%) corresponded to 103±13 pmol min−1 mg protein−1 for ETTh,
and 61±2 pmol min−1 mg protein−1 for CTTh. Note that endogenous ET (accumulated
during cell culture from calf serum; 28±7 pmol mg protein−1 for off-state cells and
62±1 pmol mg protein−1 for on-state cells) was determined with paired dishes by
incubation in uptake buffer without ET and subtracted.
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human cell lines based on the simple tetracycline repressor [5]. As
there is no integration of vector into the genome, clonal isolation of
transfected cells is not necessary; we thus use cell pools rather than
single cell clones. Expression is turned on by addition of 1 μg/ml
doxycycline to the culture medium for about 20 h. With, e.g., ETTh,
this system provides a high rate of carrier-mediated transport in the
on-state (=100%) and a low rate (4%) in the off-state (=leakFig. 3. Carnitine transport activity of ETTh mutants (ﬁrst set) relative to wild-type CTTh. In
transfected 293 cells. Shown is mean±SEM (n=2–3, assays performed on different days). A
eGFP; average (n=12) CT accumulation 12.8±0.9 pmol min−1 mg protein−1) and negat
always transfected and assayed in parallel.expression) [5]. The data shown in Fig. 2 validate sufﬁcient signal over
background: carnitine uptake mediated by exogenous wild-type CTTh
was much higher than nonspeciﬁc accumulation due to diffusion,
binding, endogenous CTTh [1], and leak expression of CTTh.
Fig. 3 shows initial rates of uptake of 3H-carnitine of the ﬁrst set of
mutants relative to wild-type CTTh (100%). Background accumulation
was estimated with wild-type ETTh and subtracted from all rates.
Both controls were always transfected and measured in parallel.
Mutations only within a single TMS were virtually without effect
on uptake of carnitine (Fig. 3a). However, the combination of changes
in TMS 7 and 10 (mutant e7.10) clearly promoted uptake of carnitine
(8.8% relative to CTTh). A further substantial increase to 15.7% was
achieved with mutant e5.7.10 (Fig 3b). Surprisingly, the substitutions
in TMS 11 reduced carnitine transport.
In the second set of ETTh mutants, additional substitutions in TMS
6, 8, 9, and 12 were added to mutant e5.7.10. The changes in TMS
8 and particularly in 9 and 12 further increased carnitine transport
(Fig. 4a). Again, more prominent increases were seen with combina-
tions of the mutated segments; the highest rate was achieved by
construct e5.7.8.9.10.12 which displayed 35% of wild-type CTTh
carnitine transport activity (Fig. 4b). By contrast, the change in TMS
6 reduced transport activity (Fig. 4a).
A decrease in carnitine transport relative to the respective
reference construct was also observed with 3 mutants with additional
substitutions (cf., Table 1): mutant e7a.10 (7.5±0.4%) which is e7.10
(10.8±0.8%) plus 2 further changes in TMS 7, mutant eA (5.5±0.5%)
which is e7.10 (10.8±0.8%) plus 2 further changes in the external
loop between TMS 9 and 10, and mutant eB (14.5±3.9%) which is
e5.7.10.12 (18.6±4.5%) plus 1 further change in the external loop
between TMS 11 and 12. Finally, mutant eC (7.3±0.4%), which
contains all 23 mutations from Table 1, was much less active than our
best mutant e5.7.8.9.10.12 with 15 changes (34.7±4.2%).
3.3. ETTh mutants—ergothioneine transport
The mutants that had shown a progressive increase of carnitine
transport were also assayed for ET transport. Paired dishes were used
to measure uptake of carnitine (described above) and ET underitial rates of uptake of 3H-carnitine (0.1 μmol/l; 1 min) were determined with stably
ccumulation by wild-type ETTh was subtracted from all rates. Positive (wild-type CTTh-
ive control cells (wild-type ETTh-eGFP, 0.52±0.03 pmol min−1 mg protein−1) were
Fig. 4. Carnitine transport activity of ETTh mutants (second set) relative to wild-type CTTh. See legend to Fig. 3 for experimental conditions.
Table 2
Afﬁnity for carnitine of selected ETTh mutants.
Mutant Km
(μmol/l)
95% CI Vmax
(nmol min−1 mg protein−1)
CTTh wild-type 15 11–21 1.08±0.04
e5.7.10 280 220–360 1.94±0.09
e5.7.8.10 230 210–270 2.08±0.04
e5.7.9.10 140 90–200 1.68±0.10
e5.7.10.12 210 140–320 1.72±0.12
e5.7.8.9.10 140 110–180 2.66±0.11
e5.7.8.9.10.12 98 68–140 1.72±0.08
Given is the Km with the corresponding 95% conﬁdence interval (CI) and the Vmax with
corresponding SD measured by saturation of uptake of 3H-carnitine (n=18). Note that
the different mutants were not measured in parallel; hence, Vmax/Km cannot be
compared.
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with ET (10 μmol/l in uptake buffer), and then the ET content was
measured by LC-MS/MS. The initial endogenous ET content was
estimated and subtracted separately for each cell line with paired
dishes that were incubated with uptake buffer without ET. Note that
this simple approach, which reduces the number of dishes over the
precise method [2] by 50%, yields the sum of speciﬁc (catalyzed by the
exogenous transporter) and nonspeciﬁc accumulation. Yet this sum
overestimates true exogenous ET transport activity only very slightly
here, since 293 cells do not express endogenous ETTh [3], and since
nonspeciﬁc uptake of ET is very low. Uptake mediated by exogenous
ETTh was much higher than nonspeciﬁc background accumulation of
ET due to diffusion, binding, and leak expression of ETTh (Fig. 2).
Fig. 5 shows accumulation of ET relative to wild-type ETTh (100%).
Surprisingly, efﬁciency of transport of ET was fully maintained or even
clearly increased for all mutants except eC, the all-substitutions
construct, which was only at 40.2±5.3% relative to wild-type. Thus,
the increase in CT transport (Figs. 3 and 4) does not correlate with a
decrease in ET transport.
3.4. ETTh mutants—substrate afﬁnity
Substitutions may affect substrate binding (Km) or turnover
(kcat=Vmax/Ttotal). Mutations that improve binding of substrate to
the carrier should increase afﬁnity, i.e., decrease the Km value.
Saturation of transport of carnitine was determined with selected
mutants (Table 2); note that because of the poor signal-to-noise ratio,
we have not analyzed wild-type ETTh here. The results indicate that
increased carnitine transport as described above correlates well with
increased afﬁnity: mutant e5.7.8.9.10.12 (Km=98 μmol/l) has 3-fold
higher afﬁnity than mutant e5.7.10 (280 μmol/l). However, the
afﬁnity of wild-type CTTh is still 7-fold higher (15 μmol/l). A relatively
strong increase in afﬁnity was imparted by the changes in TMS 9.
Saturation of transport of ET was analyzed with mutant
e5.7.8.9.10.12 to see whether this mutant—profoundly altered, but
with full transport efﬁciency for ET (Fig. 5)—still had the originalafﬁnity. Our results (Fig. 6) indicate markedly reduced afﬁnity
(66 μmol/l; 95% conﬁdence interval (95% CI), 48–90 μmol/l) vs. wild-
type ETTh (16 μmol/l; 95% CI, 12–22 μmol/l). Since here both cell lines
were transfected and analyzed in parallel, a comparison of Vmax/Km
is possible. With virtually identical numbers (30.0 vs. 31.9 μl min−1 mg
protein−1), it can be concluded that the mutant has a 4-fold higher
turnover number than wild-type ETTh.
3.5. CTTh mutants—ergothioneine transport
A set of CTTh mutants was created analogous to the ETTh mutants
(see Table 1 for designations and exact descriptions). Again, all
constructs contained eGFP at the C-terminus, and all mutants showed
expression levels (FACS analysis, data not shown) and membrane
localization (ﬂuorescence microscopy; Supplementary Fig. 2b) like
the wild-type carriers. Accumulation of ET, measured by LC-MS/MS as
above, was not consistently increased over wild-type CTTh for any of
the examined mutants (each assayed 2 or 3 times on different days;
data not shown). Mutants c9, c12a, c9.12a, and c7a.9.10 were not
analyzed here.
Fig. 5. Ergothioneine transport activity of ETThmutants relative to wild-type ETTh. Initial rates of uptake of unlabeled ET (10 μmol/l; 1 min) were determined with stably transfected
293 cells. Shown is mean±SEM (n=2–3, assays performed on different days). For each cell line, endogenous ET (accumulated during cell culture from FCS) wasmeasured in parallel
by incubation in uptake buffer without ET and subtracted. Positive (wild-type ETTh-eGFP; average (n=14) ET accumulation 770±90 pmol min−1 mg protein−1) and negative
control cells (wild-type CTTh-eGFP, 7±1 pmol min−1 mg protein−1) were always transfected and assayed in parallel.
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Fig. 7 shows initial rates of uptake of 3H-carnitine of all CTTh
mutants relative to wild-type CTTh (100%). As for the ETTh mutants,
background accumulation was estimated with wild-type ETTh and
subtracted from all rates. Both controls were always transfected and
measured in parallel. Each mutant was assayed 2 or 3 times on
different days.
By contrast to the ETTh mutants described above, a marked loss-
of-function was achieved easily by 1 to 4 amino acid substitutions
within a single TMS (Fig. 7a). Changes in TMS 5 or 7 caused a strongFig. 6. Saturation of uptake of ET mediated by wild-type ETTh and ETTh mutant e5.7.8.9.10.12
is mean±SEM (n=3). Speciﬁc uptake equals total content minus endogenous content divi
cells increased linearly with ET concentration, slope=0.18 μl min−1 mg protein−1. Vmax=0
transformation.reduction of carnitine transport, and changes in TMS 10, 12, or 9 a
moderate reduction. The changes in TMS 11 had no effect.
The combination c7a.10 was used as reference for further
constructs (Fig. 7b). Additional changes in either TMS 9 or TMS 12
had no effect. However, additional changes in TMS 5 generated totally
inactive mutants (c5.7a.10 and 3 further mutants that contain this
set). Surprisingly, addition of changes in TMS 8 and particularly in
TMS 11 to c7a.10 increased transport of carnitine. Analogously,
mutant c5b.11 showed much higher transport than c5b. By contrast,
transport by mutant c9.12a (37.1%) was clearly reduced compared to
the corresponding base mutants c9 (82.9%) and c12a (51.3%).. An uptake period of 1 min was chosen to approximate initial rates of transport. Shown
ded by uptake time minus nonspeciﬁc uptake. Nonspeciﬁc uptake with wild-type ETTh
.51±0.02 (wild-type) or 2.0±0.1 nmol min−1 mg protein−1. Insets: Eadie–Scatchard
Fig. 7. Carnitine transport activity of CTThmutants relative to wild-type CTTh. Initial rates of uptake of 3H-carnitine (0.1 μmol/l; 1 min) were determined with stably transfected 293
cells. Shown is mean±SEM (n=2–3, assays performed on different days). Accumulation by wild-type ETTh was subtracted from all rates. Positive (wild-type CTTh-eGFP; average
(n=9) CT accumulation 13±3 pmol min−1 mg protein−1) and negative control cells (wild-type ETTh-eGFP, 0.7±0.2 pmol min−1 mg protein−1) were always transfected and
assayed in parallel.
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The aim of the present workwas to alter the substrate speciﬁcity of
an integral membrane transport protein. To accomplish such a gain-
of-function is a much greater challenge than to delete function—the
latter can easily be achieved by a myriad of single amino acid
substitutions. Point mutations were selected based on potentially
momentous differences in the evolutionary analysis of mammalian
orthologues of ETT and CTT (Supplementary Fig. 1). We have indeed
succeeded to impart a high rate of carnitine transport—35% relative to
the wild-type carnitine transporter (Fig. 4b)—to ETT, a carrier that
originally totally rejects CT as substrate. Note that Amat di San Filippo
et al. [9] have reported transport of carnitine for a chimeric constructwhere amino acids 1–193 of ETTh replaced the corresponding part of
CTTh at only about 50% relative to wild-type CTTh. Hence, since we
have not made any changes in this region, we could only expect to
achieve this much; our mutant e5.7.8.9.10.12 comes impressively
close to this mark.
Our results establish that substrate discrimination is based on
multiple positions distributed to at least 6 transmembrane segments:
5, 7, 8, 9, 10, and 12. Note that further contacts to substrate can be
expected among those amino acids that are identical in ETT and CTT
[10–14], but these do not contribute to discrimination. Our results
agree with reports about other SLC22 carriers and the glucose
transporter GLUT1 (which belongs to the same superfamily) where
residues critical for transport activity were found in TMS 5 [15,16],
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study with ETT–CTT–chimera mentioned above [9], 2 regions
essential for carnitine transport were identiﬁed (CTT sequence
numbering): 341–453 (containing TMS 7–10) and 454–557 (TMS
11–12); further contacts to substrate were postulated between 194
and 340 (TMS 4–6). This basically agrees with our results. However,
our TMS-based approach provides higher resolution and thus more
differentiated insight: for example, our data suggest that changes in
TMS 12 affect substrate afﬁnity (Table 2); by contrast, the 454–557
(TMS 11–12) replacement [9] reduced Vmax, but did not alter Km.
Moreover, only transport of carnitine was analyzed then since ET was
unknown as physiological substrate of ETT at the time. It is quite
remarkable that our best construct, e5.7.8.9.10.12, contains only 15
amino acid changes; since we have grouped potentially relevant
substitutions in TMS and not tested each mutation individually, the
minimum number needed for the same level of function might even
be lower. Increased carnitine transport correlates well with increased
afﬁnity (Table 2).
Amazingly, complementary substitutions in CTT could not provoke
any transport activity for ET whatsoever. In similar contrast, CT
transport by CTT mutants was easily abolished by very few
substitutions (Fig. 7), whereas ET transport by ETT mutants was
fully maintained even with the construct most active in CT transport
(Fig. 5). To explain these results, we suggest that ETT and CTT have not
only dissimilar substrate binding sites but also dissimilar pathways for
conformational change. In other words, some parts of the carriers
move differently during turnover. It appears that the ET movement
pathway of ETT accomodates CT—a smaller and more ﬂexible
molecule (Fig. 1)—well, but the CT movement pathway of CTT cannot
accomodate ET. This model suggests that we have sufﬁciently
transformed binding sites to establish CT transport by ETT mutants
and to abolish CT transport by CTT mutants. However, we have not
exchanged movement pathways: ET is not transported by CTT
mutants and is still transported by ETT mutants. From another
perspective, CT is excluded from ETT by binding, and ET is excluded
from CTT by movement.
We have constructed several ETTh mutants that contain substitu-
tions (Table 1, columns 4, 5+8, 9, 14+15, 18+19, and 20) which
clearly reduced carnitine transport. This was contrary to our naive
expectation that any additional mutation would either increase CT
transport or have no effect. Changes in these positions probably
impair the movement pathway (“spanner in the works”) and thus
reduce rates of transport. From another perspective, a relative
reduction of transport presumably indicates a position involved in
turnover movement rather than mere substrate binding. In accor-
dance, in the report by Amat di San Filippo et al. [9], mutations (CTT
sequence numbering) R341L, L424Y, and T429I (which in our
assignment of TMS are located not in, but between transmembrane
segments) reduced Vmax, but did not affect Km. Further complemen-
tary transitions are necessary to establish a different movement
pathway. Potential positions (mostly outside the transmembrane
segments) are indicated in Supplementary Fig. 1. Of course, we cannot
exclude that trivial substitutions (e.g., V⇔ I) may have an effect.
Several ETTh mutants showed ET transport rates clearly higher
than wild-type (Fig. 5). As suggested from Fig. 6, this is most likely
caused by a higher turnover number. Similarly, transitions in TMS
8 and 11 increased CT transport by some CTTh mutants (Fig. 7). This
suggests that both wild-type carriers operate slower than physically
possible. In other words, accurate substrate discrimination is more
important than high substrate ﬂux.
ETT and CTT belong to the same superfamily as 3 bacterial carriers
with known three-dimensional structures: glycerol-3-phosphate
transporter GlpT from Escherichia coli [25], lactose permease LacY
from E. coli [26], and oxalate transporter OxlT from Oxalobacter
formigenes [27]. It was deduced from these structures that TMS 3, 6, 9,
and 12 are not involved in substrate binding or translocation, but—asscaffolding or pillars—encircle and stabilize the inner bundle of the
other helices. This notion was fully supported by cysteine-scanning
mutagenesis and cysteine reagent accessibility assays of TMS 9 and 12
of GLUT1 [28,29]. However, since our mutant e5.7.10 with about 15%
carnitine transport relative to wild-type was still far off the 50% mark,
and since our evolutionary analysis indicated interesting positions in
TMS 6, 9, and 12, they were included in the second set of ETTh
mutants. Indeed, transitions in TMS 9 and 12 clearly promoted uptake
of carnitine and increased afﬁnity. It is therefore a major and
unexpected ﬁnding of the present work that TMS 9 and 12 are not
inert, but contribute to substrate discrimination, either by direct
binding or by indirectly guiding other segments. These results
illustrate that the available bacterial structures can fail to predict
precise substrate contacts of SLC22 transporters. In fact, it is not even
possible to generate a reasonable amino acid sequence alignment
between the bacterial transporters and ETT or CTT. Moreover, static
structures cannot reveal the proposed different movement pathways.
In conclusion, we have managed to impart by point mutations a
high rate of carnitine transport to ETT, a carrier that originally totally
rejects CT as substrate. Our data indicate amino acids critical for
substrate discrimination not only in transmembrane segments 5, 7, 8,
and 10 but also in segments 9 and 12 which were hitherto considered
as unimportant. We propose that ETT and CTT use dissimilar
pathways for conformational change, in addition to dissimilar
substrate binding sites, to discriminate substrates.
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